RU58841 – Powder, 5 grams
RU58841 – Powder, 5 grams
Currently unavailable
NovaMeds
Sunifiram (DM-235) is a synthetic pyrrolidinone-derived compound structurally distinct from the classical racetam family despite sharing a related core scaffold, investigated for proposed positive allosteric modulation of AMPA-type glutamate receptors.
Presentation: Sunifiram – powder, 10 grams.
Illustrative packaging generated with AI.
Not for human or veterinary use.
Sunifiram (DM-235) is a synthetic pyrrolidinone-derived compound structurally distinct from the classical racetam family despite sharing a related core scaffold, investigated for proposed positive allosteric modulation of AMPA-type glutamate receptors. Research interest centers on its reported high in vitro potency relative to piracetam-class compounds at substantially lower concentrations.
Research applications include AMPA receptor potentiator pharmacology, glutamatergic signalling research, and structure-activity comparison within the pyrrolidinone-derivative compound series.
| Chemical Formula | C14H18N2O2 |
|---|---|
| Synonyms | DM-235 |
| Molar Mass | 246.304 g/mol |
| CAS Number | 314728-85-3 |
| PubChem CID | 4223812 |
| Total Compound Content | 10 grams |
| Shelf Life | 36 months |
Sunifiram is studied as a positive allosteric modulator candidate at AMPA-type ionotropic glutamate receptors, a mechanism investigated using patch-clamp electrophysiology to characterise changes in AMPA receptor-mediated current amplitude and desensitization kinetics in the presence of the compound. Comparative potency studies position sunifiram within structure-activity relationship research examining how its specific pyrrolidinone-derived substituent pattern relates to reported nanomolar-range activity, in contrast to the typically higher concentrations required for classical racetam-family compounds in similar assay systems. Independently third-party HPLC-tested; COA available per batch.
Sunifiram shares a pyrrolidinone-derived structural lineage conceptually related to the racetam family but is synthesized via a distinct chemical route and carries substituents not present in piracetam, oxiracetam, or other classical racetam-family compounds. This structural distinction is the basis for research comparing sunifiram’s receptor-binding and functional potency profile against established racetam compounds, particularly given reports of substantially different potency ranges between the two groups in similar assay systems.
Patch-clamp electrophysiology in cultured neurons, brain slice preparations, or heterologous expression systems is the standard method for characterising sunifiram’s effects on AMPA receptor-mediated currents, with key readouts including peak current amplitude, desensitization rate, and deactivation kinetics in the presence versus absence of the compound. These functional measurements are used alongside receptor-binding assays to determine whether sunifiram acts at an allosteric site distinct from the glutamate orthosteric binding site, consistent with a positive allosteric modulator mechanism.
Reports of sunifiram’s in vitro activity describe substantially lower effective concentrations than those required for classical racetam-family compounds in comparable assay systems, prompting researchers to use nanomolar-to-low-micromolar concentration ranges when establishing dose-response curves for sunifiram, in contrast to the micromolar-to-millimolar ranges typically required for piracetam-class compounds. Researchers should empirically establish the relevant concentration range for their specific assay system and cell model rather than assuming direct potency transfer from other reported studies.